Capricor Therapeutics Inc — Cash Flow (NASDAQ:CAPR) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Cash from operating activities -10.05 M-16.81 M4.92 M-25.6 M-40 M -61.04 M Cash from investing activities 5.44 M-1.2 M-35.07 M5.11 M-116.18 M -68.99 M Cash from financing activities 33.38 M20.23 M4.87 M25.58 M152.77 M 81.16 M Free cash flow -10.6 M-18.01 M2.92 M-26.91 M-41.16 M -62.77 M

뉴스

오펜하이머, 카프리코에 ’매수’ 등급 재확인... 목표가 54달러 유지

Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

Capricor to submit HOPE-3 data to FDA for DMD therapy review

Capricor Therapeutics, Cantor Fitzgerald 투자의견 재확인

Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald

카프리코, Cantor Fitzgerald ’비중확대’ 투자의견 유지

Cantor Fitzgerald reiterates Overweight rating on Capricor stock

Capricor Therapeutics Stock: A High Risk/High Reward Name (NASDAQ:CAPR)

Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

파이퍼 샌들러, 카프리코 주식 등급 재확인 및 2026년 최선호주 선정